The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Research Report 2025
Synopsis
PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
The global PARP (Poly ADP-ribose Polymerase) Inhibitors market was valued at US$ 2861 million in 2023 and is anticipated to reach US$ 21490 million by 2030, witnessing a CAGR of 32.8% during the forecast period 2024-2030.
North American market for PARP (Poly ADP-ribose Polymerase) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PARP (Poly ADP-ribose Polymerase) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for PARP (Poly ADP-ribose Polymerase) Inhibitors in Ovarian Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of PARP (Poly ADP-ribose Polymerase) Inhibitors include AbbVie, Pfizer, AstraZeneca, GlaxoSmithKline, Clovis Oncology and Everest Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PARP (Poly ADP-ribose Polymerase) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PARP (Poly ADP-ribose Polymerase) Inhibitors.
Report Scope
The PARP (Poly ADP-ribose Polymerase) Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PARP (Poly ADP-ribose Polymerase) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PARP (Poly ADP-ribose Polymerase) Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals
Segment by Type
Olaparib
Talazoparib
Segment by Application
Ovarian Cancer
Breast Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PARP (Poly ADP-ribose Polymerase) Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
The global PARP (Poly ADP-ribose Polymerase) Inhibitors market was valued at US$ 2861 million in 2023 and is anticipated to reach US$ 21490 million by 2030, witnessing a CAGR of 32.8% during the forecast period 2024-2030.
North American market for PARP (Poly ADP-ribose Polymerase) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PARP (Poly ADP-ribose Polymerase) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for PARP (Poly ADP-ribose Polymerase) Inhibitors in Ovarian Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of PARP (Poly ADP-ribose Polymerase) Inhibitors include AbbVie, Pfizer, AstraZeneca, GlaxoSmithKline, Clovis Oncology and Everest Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PARP (Poly ADP-ribose Polymerase) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PARP (Poly ADP-ribose Polymerase) Inhibitors.
Report Scope
The PARP (Poly ADP-ribose Polymerase) Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PARP (Poly ADP-ribose Polymerase) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PARP (Poly ADP-ribose Polymerase) Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals
Segment by Type
Olaparib
Talazoparib
Segment by Application
Ovarian Cancer
Breast Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PARP (Poly ADP-ribose Polymerase) Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Olaparib
1.2.3 Talazoparib
1.3 Market by Application
1.3.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Perspective (2019-2030)
2.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Trends by Region
2.2.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Dynamics
2.3.1 PARP (Poly ADP-ribose Polymerase) Inhibitors Industry Trends
2.3.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Drivers
2.3.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Challenges
2.3.4 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PARP (Poly ADP-ribose Polymerase) Inhibitors Players by Revenue
3.1.1 Global Top PARP (Poly ADP-ribose Polymerase) Inhibitors Players by Revenue (2019-2024)
3.1.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue
3.4 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Concentration Ratio
3.4.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in 2023
3.5 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players Head office and Area Served
3.6 Key Players PARP (Poly ADP-ribose Polymerase) Inhibitors Product Solution and Service
3.7 Date of Enter into PARP (Poly ADP-ribose Polymerase) Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PARP (Poly ADP-ribose Polymerase) Inhibitors Breakdown Data by Type
4.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Forecasted Market Size by Type (2025-2030)
5 PARP (Poly ADP-ribose Polymerase) Inhibitors Breakdown Data by Application
5.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2019-2030)
6.2 North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2019-2024)
6.4 North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2019-2030)
7.2 Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2019-2024)
7.4 Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2019-2030)
9.2 Latin America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2019-2024)
9.4 Latin America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
11.1.4 AbbVie Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
11.2.4 Pfizer Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
11.3.4 AstraZeneca Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2019-2024)
11.3.5 AstraZeneca Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
11.4.4 GlaxoSmithKline Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Clovis Oncology
11.5.1 Clovis Oncology Company Detail
11.5.2 Clovis Oncology Business Overview
11.5.3 Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
11.5.4 Clovis Oncology Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2019-2024)
11.5.5 Clovis Oncology Recent Development
11.6 Everest Pharmaceuticals
11.6.1 Everest Pharmaceuticals Company Detail
11.6.2 Everest Pharmaceuticals Business Overview
11.6.3 Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
11.6.4 Everest Pharmaceuticals Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2019-2024)
11.6.5 Everest Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
